Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1975 Jul;8(1):63–66. doi: 10.1128/aac.8.1.63

Effects of Renal Failure and Dialysis on Cefazolin Pharmacokinetics

T Madhavan 1, Kathy Yaremchuk 1, Nathan Levin 1, Evelyn Fisher 1, Frank Cox 1, Keith Burch 1, Erwin Haas 1, Don Pohlod 1, Edward L Quinn 1
PMCID: PMC429262  PMID: 1164008

Abstract

Serum and urinary levels of cefazolin were determined after a 500-mg parenteral dose in eight azotemic volunteers. The mean peak serum concentration was 1.5 to 5 times the levels obtained in nonazotemic patients. The serum half-life of cefazolin was increased significantly. In patients on dialysis, the mean serum half-life of cefazolin was 4.05 h during (or after) hemodialysis, and 32.1 h during (or after) peritoneal dialysis. There was a significant decrease in cefazolin removal when dialysate flow or membrane surface area of the dialyzer were decreased. It was also shown that one circuit through the dialysis unit caused measurable decrease in cefazolin concentration. These data and previously published reports suggest: (i) the maintenance dose of cefazolin can be decreased in azotemic patients; (ii) patients on hemodialysis will require an additional half dose after dialysis because of efficient removal during hemodialysis; and (iii) patients on peritoneal dialysis do not require an extra dose.

Full text

PDF
63

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergeron M. G., Brusch J. L., Barza M., Weinstein L. Bactericidal activity and pharmacology of cefazolin. Antimicrob Agents Chemother. 1973 Oct;4(4):396–401. doi: 10.1128/aac.4.4.396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Craig W. A., Welling P. G., Jackson T. C., Kunin C. M. Pharmacology of cefazolin and other cephalosporins in patients with renal insufficiency. J Infect Dis. 1973 Oct;128(Suppl):S347–S345. doi: 10.1093/infdis/128.supplement_2.s347. [DOI] [PubMed] [Google Scholar]
  3. Levison M. E., Levison S. P., Ries K., Kaye D. Pharmacology of cefazolin in patients with normal and abnormal renal function. J Infect Dis. 1973 Oct;128(Suppl):S354–S357. doi: 10.1093/infdis/128.supplement_2.s354. [DOI] [PubMed] [Google Scholar]
  4. Madhavan T., Quinn E. L., Freimer E., Fisher E. J., Cox F., Burch K., Pohlod D. Clinical studies of cefazolin and comparison with other cephalosporins. Antimicrob Agents Chemother. 1973 Nov;4(5):525–531. doi: 10.1128/aac.4.5.525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. McCloskey R. V., Forland M. F., Sweeney M. J., Lawrence D. N. Hemodialysis of cefazolin. J Infect Dis. 1973 Oct;128(Suppl):S358–S356. doi: 10.1093/infdis/128.supplement_2.s358. [DOI] [PubMed] [Google Scholar]
  6. Reller L. B., Karney W. W., Beaty H. N., Holmes K. K., Turck M. Evaluation of cefazolin, a new cephalosporin antibiotic. Antimicrob Agents Chemother. 1973 Apr;3(4):488–497. doi: 10.1128/aac.3.4.488. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES